Ulf Hannelius
Vermogen: 50 095 $ op 31-07-2026
Vermogen: 50 095 $ op 31-07-2026
Ulf Hannelius is currently Chairman at Diamyd Biomanufacturing AB and Director at Mainly AB since 2021.
Formerly, Dr. Hannelius was President & Chief Executive Officer at Diamyd Medical AB from 2016 to 2026.
Education includes a doctorate from Karolinska Institutet and an MBA from Stockholm School of Economics.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-08-2025 | 463.973 ( 0,31% ) | 50 095 $ | 31-07-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
Mainly AB
Mainly AB Packaged SoftwareTechnology Services Develops an AI research engineer platform | Directeur/Bestuurslid | 22-02-2021 |
| Bedrijven | Functie | Einde |
|---|---|---|
| DIAMYD MEDICAL AB | Algemeen Directeur | 22-04-2026 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stockholm School of Economics
Stockholm School of Economics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Diamyd Medical AB
Diamyd Medical AB Pharmaceuticals: MajorHealth Technology Develops precision medicine drugs for type 1 diabetes and other forms of autoimmune diabetes | Health Technology |
Mainly AB
Mainly AB Packaged SoftwareTechnology Services Develops an AI research engineer platform | Technology Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau